In a significant shift, there is new evidence that pharma and biotech companies are increasingly turning away from China and looking at other emerging markets to drive growth.
During its latest quarterly earnings call, AstraZeneca PLC, traditionally one of the staunchest believers in the China market, indicated...
Welcome to Scrip
Create an account to read this article
Already a subscriber?